Antihipertansif İlaçlar
Özet
Hipertansiyon, sürekli kan basıncı yüksekliğiyle seyreden ve ciddi komplikasyonlara yol açabilen yaygın bir sistemik hastalıktır. Tedavide temel amaç kan basıncını aniden düşürmek değil, hedef organ hasarını ve buna bağlı riskleri azaltmaktır. Tedavi yaklaşımları parenteral ve oral ilaçlar olarak iki ana sınıfta gruplandırılır. Akut hedef organ hasarının eşlik ettiği hipertansif acillerde, kan basıncını hızlı ve kontrollü şekilde düşürmek amacıyla yoğun bakım şartlarında intravenöz (iv) parenteral ilaçlar (nitrogliserin, nitroprussid, klevidipin, nikardipin vb.) tercih edilir. Kronik hipertansiyon tedavisinde ise kalsiyum kanal blokerleri, ACE inhibitörleri, ARB'ler, diüretikler ve beta blokerler gibi oral ajanlar kullanılır. İlaç seçimi; hastanın yaşına, ırkına ve kalp yetmezliği, diyabet veya böbrek hastalığı gibi eşlik eden komorbiditelerine göre bireyselleştirilir. Kontrolsüz hipertansiyon, semptom göstermeden ilerleyebildiği için "sessiz katil" olarak adlandırılmakta olup miyokard enfarktüsü, felç ve böbrek yetmezliği gibi ölümcül sonuçlar doğurabilmektedir.
Hypertension is a common systemic disease characterized by persistently elevated blood pressure that can lead to serious complications. The primary goal of treatment is not merely lowering blood pressure, but preventing complications and reducing overall risk. Therapeutic approaches are grouped into two main categories as parenteral and oral drugs. In hypertensive emergencies accompanied by acute target organ damage, intravenous parenteral agents (such as nitroglycerin, nitroprusside, clevidipine, and nicardipine) are preferred under intensive care conditions to lower blood pressure rapidly and controllably. For chronic hypertension treatment, oral agents such as calcium channel blockers, ACE inhibitors, ARBs, diuretics, and beta-blockers are utilized. Drug selection is individualized based on factors including the patient's age, race, and comorbidities like heart failure, diabetes, or renal disease. Uncontrolled hypertension, which often progresses without noticeable symptoms and is thus termed a "silent killer," can result in fatal consequences such as myocardial infarction, stroke, and renal failure.
Referanslar
Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA. 1994; 91:7583.
William J Elliott (2019) Drugs used for the treatment of hypertensive emergencies https://www.uptodate.com/contents/drugs-used-for-the-treatment-of-hypertensive-emergencies (May 2021)
Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet. 1984; 9:239.
Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs 2008; 68:283-97.
Padilla Ramos A, Varon J. Current and newer agents for hypertensive emergencies. Curr Hypertens Rep. 2014; 16:450.
Keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014; 74:1947-1960.
Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008; 107:1110-21.
Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens. 1994; 7:623.
Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001; 345:1548.
White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989; 149:870.
Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993; 95:161.
Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. CritCare. 2011; 15:R157.
Campbell P, Baker WL, Bendel SD, et al. Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified. J Am Soc Hypertens. 2011; 5:473.
14 Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med. 1995; 155:2217.
Paul N. Fiorilli and Emile R. Mohler. Rutherford'sVascular Surgery and Endovascular Therapy. Anton P Sidawy, Bruce A Perler. Atherosclerotic Risk Factors: Hypertension. Elservier Health Sciences Publishing. 2018.Chapter 14, 153-163.
Park JB, Schiffrin EL: Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep. 2000; 2: 280-288.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000; 342:145-153.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):703-13. Erratum in: BMJ 1999 Jan 2;318(7175):29. PMID: 9732337; PMCID: PMC28659.
Ronald G. Victor. Goldman’s-Cecil Medicine(24th edition). Arterial Hypertension . Publishing 2011: 443-456.
20,.Singer DR, Kite A: Management of hypertension in peripheral arterial disease: Does the choice of drugs matter?. Eur J Vasc Endovasc Surg. 2008; 35:701-708.
Cooper WO, Hernandez-Diaz S, Arbogast PG, et. al.:Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354: 2443-2451.
Messerli FH, Grossman EF, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998; 279:1903-1907.
Carlberg B, Samuelsson OF, Lindholm LH: Atenolol in hypertension: Is it a wise choice?. Lancet. 2004; 364:1684-1689.
Lindholm LH, Carlberg BF, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366:1545-1553.
Khan N, McAlister FA: Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ. 2006; 174:1737-1742.
Marik PE, Varon J. Hypertensive crises: Challenges and management. Chest. 2007; 131:1949.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206.
